Literature DB >> 8022774

Infection and immunoregulation of T lymphocytes by parainfluenza virus type 3.

S Sieg1, C Muro-Cacho, S Robertson, Y Huang, D Kaplan.   

Abstract

Human parainfluenza virus type 3 (HPIV3) is a major cause of disease in newborns and infants. It also has a striking potential to reinfect individuals throughout their lives, suggesting that HPIV3 does not induce lifelong immunity; however, the operative mechanism for the failure to prevent reinfection is not known. We have assessed the potential of the virus to infect nontransformed human T lymphocytes and have found that T cells are readily infected by the virus. Productive infection requires activation of the T cells and results in a marked inhibition of proliferation. Furthermore, our results indicate that exposure to the virus, even without overt expression of viral proteins as detected by immunohistology, profoundly alters the functional capacity of the T cells. The capacity of the virus to regulate T-lymphocyte function may play an important role in the failure of the virus to induce lifelong immunity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8022774      PMCID: PMC44187          DOI: 10.1073/pnas.91.14.6293

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  MYXOVIRUSES: PARAINFLUENZA.

Authors:  R M CHANOCK; R H PARROTT; K M JOHNSON; A Z KAPIKIAN; J A BELL
Journal:  Am Rev Respir Dis       Date:  1963-09

Review 2.  Molecular anatomy of viral persistence.

Authors:  M B Oldstone
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Persistent infection with parainfluenza type 3 virus in man.

Authors:  P A Gross; R H Green; M G Curnen
Journal:  Am Rev Respir Dis       Date:  1973-10

4.  The Tecumseh study of respiratory illness. V. Patterns of infection with the parainfluenzaviruses.

Authors:  A S Monto
Journal:  Am J Epidemiol       Date:  1973-05       Impact factor: 4.897

5.  Replication and persistence of measles virus in defined subpopulations of human leukocytes.

Authors:  B S Joseph; P W Lampert; M B Oldstone
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

6.  Interaction between 6/94 virus, a parainfluenza type 1 strain, and human leukocytes.

Authors:  M A Verini; F S Lief
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

7.  Mumps virus replication in human lymphoid cell lines and in peripheral blood lymphocytes: preference for T cells.

Authors:  B Fleischer; H W Kreth
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

8.  Persistent parainfluenza virus shedding during isolation at the South Pole.

Authors:  H G Muchmore; A J Parkinson; J E Humphries; E N Scott; D A McIntosh; L V Scott; M K Cooney; J A Miles
Journal:  Nature       Date:  1981-01-15       Impact factor: 49.962

9.  Natural history of parainfluenza virus infection in childhood.

Authors:  R Welliver; D T Wong; T S Choi; P L Ogra
Journal:  J Pediatr       Date:  1982-08       Impact factor: 4.406

10.  Infection of lymphocytes by a virus that aborts cytotoxic T lymphocyte activity and establishes persistent infection.

Authors:  P Borrow; A Tishon; M B Oldstone
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

View more
  13 in total

1.  Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.

Authors:  Bo Chi; Harold L Dickensheets; Kirsten M Spann; Marc A Alston; Cindy Luongo; Laure Dumoutier; Jiaying Huang; Jean-Christophe Renauld; Sergei V Kotenko; Mario Roederer; Judy A Beeler; Raymond P Donnelly; Peter L Collins; Ronald L Rabin
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Polarity of human parainfluenza virus type 3 infection in polarized human lung epithelial A549 cells: role of microfilament and microtubule.

Authors:  S Bose; A Malur; A K Banerjee
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.

Authors:  R Ray; K Meyer; F K Newman; R B Belshe
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

4.  The role of interleukin-10 in the inhibition of T-cell proliferation and apoptosis mediated by parainfluenza virus type 3.

Authors:  S Sieg; C King; Y Huang; D Kaplan
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells.

Authors:  Cyril Le Nouën; Philippa Hillyer; Shirin Munir; Christine C Winter; Thomas McCarty; Alexander Bukreyev; Peter L Collins; Ronald L Rabin; Ursula J Buchholz
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

6.  Parainfluenza virus type-3 infection attenuates the respiratory effects of antigen challenge in sensitized guinea pigs.

Authors:  E M Kudlacz; R W Knippenberg
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

7.  Human parainfluenza virus type 3 up-regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1- and CIITA-independent pathway.

Authors:  J Gao; B P De; A K Banerjee
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Natural killer cells regulate T-cell proliferation during human parainfluenza virus type 3 infection.

Authors:  Cariosa M Noone; Elaine Paget; Ellen A Lewis; Marius R Loetscher; Robert W Newman; Patricia A Johnson
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

9.  Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells.

Authors:  H Bartz; F Büning-Pfaue; O Türkel; U Schauer
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

10.  Specific inhibition of granzyme B by parainfluenza virus type 3.

Authors:  S Sieg; L Xia; Y Huang; D Kaplan
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.